Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Survey Says…

Proscia
By Author Proscia | July 29, 2023

Nathan Buchbinder, Proscia’s Chief Strategy Officer, spoke to The Pathologist to unpack the findings of the “2023 Life Sciences Digital Pathology Adoption Survey.” This research that we commissioned asked 40 senior executives from major pharmaceutical companies and contract research organizations (CROs) about the extent to which they have implemented digital pathology and the benefits it is delivering.

Our website uses cookies. By using this site, you agree to its use of cookies.